Cargando…
Lecanemab reduces brain amyloid-β and delays cognitive worsening
Lecanemab cleared amyloid-β in two-thirds and reduced the rate of cognitive and functional worsening in people with mild cognitive impairment and mild dementia due to Alzheimer disease in an 18-month double-blinded randomized placebo-controlled trial reported by van Dyck et al.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040446/ https://www.ncbi.nlm.nih.gov/pubmed/36948153 http://dx.doi.org/10.1016/j.xcrm.2023.100982 |